R&D channel feed

Roivant CEO hints at more deals shap­ing up as key Im­muno­vant da­ta loom

Last year
Pharma

In­cyte ax­es blood can­cer col­lab with Sy­ros

Last year
Deals

Phar­ma com­pa­nies look to tap med­ical so­cial in­flu­encers in new agency part­ner­ship

Last year
Marketing

Drug­mak­ers pull back af­ter Covid boom, plan­ning to cut costs as they pre­pare for in­dus­try’s next era

Last year
Pharma
Coronavirus

ALX cuts two an­ti-CD47 pro­grams just weeks af­ter Gilead stopped a piv­otal study of its own can­di­date

Last year

New Alzheimer’s drug rais­es hopes — along with ques­tions

Last year

Hen­ri­et­ta Lack­s' fam­i­ly sues Ul­tragenyx over use of im­mor­tal HeLa cell line, claim­ing un­just en­rich­ment

Last year
Law

Atre­ca holds off de­vel­op­ment on its on­ly clin­i­cal pro­gram, cuts head­count by 40%

Last year
People

J&J re­ceives fifth FDA nod for treat­ing mul­ti­ple myelo­ma, with boxed warn­ing and REMS in tow

Last year
Pharma
FDA+

Ex­clu­sive: As­traZeneca’s out­go­ing R&D chief Mene Pan­ga­los re­flects on a 14-year R&D turn­around and the in­dus­try's fu­ture

Last year
People
Pharma

Il­lu­mi­na slash­es out­look for 2023, two ex­ec­u­tives de­part

Last year

FDA+ roundup: FDA con­tin­ues to loosen stan­dard of ev­i­dence for nov­el drug ap­provals — JA­MA re­search let­ter

Last year
FDA+

Terns Phar­ma­ceu­ti­cals touts mid-stage suc­cess for NASH drug, stock falls

Last year

Gates-backed study of faster tu­ber­cu­lo­sis drug treat­ments kicks off in South Africa

Last year

No­var­tis flex­es PhI­II win for oral BTK in­hibitor in chron­ic spon­ta­neous ur­ticaria

Last year

De­nali, Take­da scrap PhI Alzheimer's drug due to safe­ty sig­nals, 'rapid­ly evolv­ing' land­scape

Last year

Oculis eye drop se­cures an­oth­er late-stage win, this time in post-cataract surgery in­flam­ma­tion and pain 

Last year

Up­dat­ed: Bay­er cuts PhII or­phan drug as it ups R&D spend­ing, ques­tions swirl around new CEO’s next moves

Last year

Up­dat­ed: No­vo Nordisk's semaglu­tide in­jec­tion re­duces car­dio­vas­cu­lar events by 20% in vast SE­LECT tri­al

Last year

Ar­cus de­pri­or­i­tizes Gilead-part­nered drug in prostate can­cer, the lat­est hic­cup in $1.6B col­lab­o­ra­tion

Last year

Nek­tar says Eli Lil­ly mis­cal­cu­lat­ed da­ta in eczema tri­al be­fore break­ing off rezpeg part­ner­ship

Last year

Ac­er­a­gen to pull out of Nas­daq and liq­ui­date as­sets, end­ing tu­mul­tuous jour­ney for Idera Phar­ma

Last year
Pharma

Bavar­i­an Nordic makes plans to sub­mit chikun­gun­ya vac­cine for ap­proval af­ter sec­ond pos­i­tive PhI­II tri­al read­out

Last year

Up­dat­ed: FDA ap­proves Bio­gen and Sage's pill for post­par­tum de­pres­sion, but re­jects use in ma­jor de­pres­sion

Last year
Pharma
First page Previous page 73747576777879 Next page Last page
A service from the Financial Times